{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:53:41Z","timestamp":1775199221389,"version":"3.50.1"},"reference-count":37,"publisher":"XMLink","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["tcpharm.org"],"crossmark-restriction":false},"short-container-title":["Transl Clin Pharmacol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.12793\/tcp.2026.34.e6","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:39:54Z","timestamp":1775191194000},"page":"1","update-policy":"https:\/\/doi.org\/10.12793\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The pH factor: unraveling drug-drug interactions in protein kinase inhibitors through the regulatory lens"],"prefix":"10.12793","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3038-4450","authenticated-orcid":false,"given":"Simona","family":"Stankeviciute","sequence":"first","affiliation":[{"name":"Parexel International UAB, LT-08130 Vilnius, Lithuania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7713-1168","authenticated-orcid":false,"given":"Ariel","family":"Tsai","sequence":"additional","affiliation":[{"name":"Parexel Netherland B.V., 1101 CC Amsterdam, Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-6359","authenticated-orcid":false,"given":"Noha","family":"Rayad","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences, Research & Development, Alexion, AstraZeneca Rare Disease, Mississauga, ON L5N 0E1, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0738-3174","authenticated-orcid":false,"given":"Matthias","family":"Kruse","sequence":"additional","affiliation":[{"name":"Parexel International GmbH, 14050 Berlin, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18617","reference":[{"key":"10.12793\/tcp.2026.34.e6_ref1","unstructured":"Food and Drug Administration. Evaluation of gastric pH-dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications [Internet]. Accessed October 1, 2024.  https:\/\/www.fda.gov\/media\/166156\/download"},{"key":"10.12793\/tcp.2026.34.e6_ref2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/clpt.2014.87","volume":"96","author":"Zhang","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.12793\/tcp.2026.34.e6_ref3","unstructured":"Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey [Internet]. Accessed October 1, 2024.  https:\/\/www.cdc.gov\/nchs\/data\/hus\/hus16.pdf#079"},{"key":"10.12793\/tcp.2026.34.e6_ref4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/curroncol28010076","volume":"28","author":"Uchiyama","year":"2021","journal-title":"Curr Oncol"},{"key":"10.12793\/tcp.2026.34.e6_ref5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","volume":"92","author":"Budha","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.12793\/tcp.2026.34.e6_ref6","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2022-156487","volume":"140","author":"Larfors","year":"2022","journal-title":"Blood"},{"key":"10.12793\/tcp.2026.34.e6_ref7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/ph18070959","volume":"18","author":"Bud\u0103u","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.12793\/tcp.2026.34.e6_ref8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","volume":"29","author":"Blume","year":"2006","journal-title":"Drug Saf"},{"key":"10.12793\/tcp.2026.34.e6_ref9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"10.12793\/tcp.2026.34.e6_ref10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf"},{"key":"10.12793\/tcp.2026.34.e6_ref11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00042737-200105000-00025","volume":"13","author":"Gerson","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.12793\/tcp.2026.34.e6_ref12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","volume":"1","author":"Paul","year":"2004","journal-title":"Int J Med Sci"},{"key":"10.12793\/tcp.2026.34.e6_ref13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol Cancer"},{"key":"10.12793\/tcp.2026.34.e6_ref14","first-page":"F217","volume":"1333","author":"Kolibaba","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.12793\/tcp.2026.34.e6_ref15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.12793\/tcp.2026.34.e6_ref16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","volume":"2","author":"Broekman","year":"2011","journal-title":"World J Clin Oncol"},{"key":"10.12793\/tcp.2026.34.e6_ref17","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2165\/00003495-200161120-00007","volume":"61","author":"Lyseng-Williamson","year":"2001","journal-title":"Drugs"},{"key":"10.12793\/tcp.2026.34.e6_ref18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.12793\/tcp.2026.34.e6_ref19","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.12793\/tcp.2026.34.e6_ref20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12248-024-00939-1","volume":"26","author":"Kollipara","year":"2024","journal-title":"AAPS J"},{"key":"10.12793\/tcp.2026.34.e6_ref21","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Drug interaction studies [Internet]. Accessed October 1, 2024.  https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521.pdf"},{"key":"10.12793\/tcp.2026.34.e6_ref22","volume-title":"Report No.: EMA\/124631\/2025. Concept paper on a guideline on investigation of drug interactions in the gastrointestinal tract","author":"European Medicines Agency (EMA)","year":"2025"},{"key":"10.12793\/tcp.2026.34.e6_ref23","volume-title":"Report No.: EMA\/497207\/2024. Question & answer on the need for bioequivalence studies with acid reducing agents (ARAs)","author":"European Medicines Agency (EMA)","year":"2024"},{"key":"10.12793\/tcp.2026.34.e6_ref24","unstructured":"European Medicines Agency (EMA). Guideline on the investigation of drug interactions [Internet]. Accessed October 1, 2024.  https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf"},{"key":"10.12793\/tcp.2026.34.e6_ref25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3390\/pharmaceutics17101266","volume":"17","author":"Loisios-Konstantinidis","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.12793\/tcp.2026.34.e6_ref26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s43441-025-00893-w","volume":"60","author":"Chen","year":"2026","journal-title":"Ther Innov Regul Sci"},{"key":"10.12793\/tcp.2026.34.e6_ref27","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","volume":"39","author":"Madabushi","year":"2022","journal-title":"Pharm Res"},{"key":"10.12793\/tcp.2026.34.e6_ref28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-020-00463-y","volume":"22","author":"Parrott","year":"2020","journal-title":"AAPS J"},{"key":"10.12793\/tcp.2026.34.e6_ref29","unstructured":"Food and Drug Administration (FDA). Rozlytrek multidisciplinary review [Internet]. Accessed April 17, 2024.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212725Orig1s000,%20212726Orig1s000MultidisciplineR.pdf"},{"key":"10.12793\/tcp.2026.34.e6_ref30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/psp4.12605","volume":"10","author":"Wang","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.12793\/tcp.2026.34.e6_ref31","unstructured":"Food and Drug Administration (FDA). Brukinsa multidisciplinary review [Internet]. Accessed April 17, 2024.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/213217Orig1s000MultidisciplineR.pdf"},{"key":"10.12793\/tcp.2026.34.e6_ref32","unstructured":"Food and Drug Administration (FDA). The use of physiologically based pharmacokinetic analyses - biopharmaceutics applications for oral drug product development, manufacturing changes, and controls [Internet]. Accessed January 10, 2025.  https:\/\/www.fda.gov\/media\/142500\/download"},{"issue":"Suppl 1","key":"10.12793\/tcp.2026.34.e6_ref33","first-page":"S160","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.12793\/tcp.2026.34.e6_ref34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1208\/s12248-021-00564-2","volume":"23","author":"Wu","year":"2021","journal-title":"AAPS J"},{"key":"10.12793\/tcp.2026.34.e6_ref35","doi-asserted-by":"crossref","first-page":"105750","DOI":"10.1016\/j.ejps.2021.105750","volume":"160","author":"Segregur","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.12793\/tcp.2026.34.e6_ref36","unstructured":"European Medicines Agency (EMA). Report No.: EMA\/451735\/2020. Assessment report: Ayvakyt [Internet]. Accessed April 17, 2024.  https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ayvakyt-epar-public-assessment-report_en.pdf"},{"key":"10.12793\/tcp.2026.34.e6_ref37","unstructured":"Food and Drug Administration (FDA). Ayvakyt multidisciplinary review [Internet]. Accessed April 17, 2024.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212608Orig1s000MultidisciplineR.pdf"}],"container-title":["Translational and Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tcpharm.org\/pdf\/10.12793\/tcp.2026.34.e6","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2026.34.e6","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2026.34.e6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:43:55Z","timestamp":1775191435000},"score":1,"resource":{"primary":{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2026.34.e6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.12793\/tcp.2026.34.e6","relation":{},"ISSN":["2289-0882","2383-5427"],"issn-type":[{"value":"2289-0882","type":"print"},{"value":"2383-5427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"2025-07-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"Copyright \u00a9 2026 Translational and Clinical Pharmacology","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"It is identical to the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/).","name":"license","label":"License","explanation":{"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}